News Search Results
Oct 16, 2025, 08:05 ET Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Oct 15, 2025, 16:30 ET Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
neurological conditions. Viatris received rights to develop and commercialize pitolisant and Spydia®, two assets in the Central Nervous System (CNS) therapy area, further expanding Viatris' portfolio of innovative products in Japan. As part of the transaction, Viatris has acquired
More news about: Viatris Inc.
Oct 15, 2025, 11:54 ET Electronic Grade SiH₄ Silane Gas Market to Reach $5.36B by 2031, Driven by Semiconductors & Solar | Valuates Reports
derivatives for solar and semiconductor use. Taiyo Nippon Sanso, Mitsui Chemicals, SIAD, Inner Mongolia Xingyang Technology, CNS, and ACE Gases. The top five companies control approximately 47% of the global market. Their strategies
More news about: Valuates Reports
Oct 15, 2025, 10:00 ET Metastatic Brain Tumor Collaborative Announces First-Ever Collaborative Grant Opportunity Focused on CNS Metastasis
innovative projects aimed at improving the diagnosis, treatment, and understanding of central nervous system (CNS) metastases. This represents the first-ever collaborative grant opportunity dedicated to CNS metastasis, made possible through the collective effort of ten leading nonprofit cancer organizations.
More news about: American Brain Tumor Association
Oct 15, 2025, 08:00 ET Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood
More news about: Indivior PLC
Oct 15, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
Conference Panel "Battleground States for Muscular Dystrophies": Tuesday, October 21 at 2:00 p.m. ET Panel "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers": Tuesday, October 21 at 2:45 p.m. ET Location: New York, NY
More news about: REGENXBIO Inc.
Oct 15, 2025, 03:30 ET Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson's disease candidate MTX325 through clinical trials
in Parkinson's disease. Phase 1a SAD/MAD was successfully completed in healthy volunteers and CSF sampling confirmed a high level of penetration into CNS. PET study further confirmed distribution into brain parenchyma. Proof-of-mechanism biomarker and imaging data in PD patients
More news about: Mission Therapeutics
Oct 14, 2025, 17:31 ET Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics,
More news about: DelveInsight Business Research, LLP
Oct 14, 2025, 09:00 ET iQure Pharma Enters into Research Collaboration with the University of Padova
2025 /PRNewswire/ -- iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced it has entered into a research collaboration with Associate Professor Laura Civiero from the University of Padova.
More news about: iQure Pharma Inc.
Oct 13, 2025, 04:00 ET Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of Neuropsychopharmacology Congress
Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference and the 38th European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam, the Netherlands. Traditional clinical trials for disorders and diseases of the central nervous system (CNS) like
More news about: Cumulus Neuroscience
Oct 12, 2025, 20:00 ET Verkada, 김기훈 신임 한국 지사장 선임
것"이라고 포부를 밝혔다. 김 지사장의 임명은 버카다가 아시아태평양 지역에서 사업 확장을 이어가는 가운데 이루어졌다. 버카다는 지난 1년간 이 지역에서 고객 기반을 60% 이상 성장시켰으며, SK쉴더스(SK Shieldus), LG CNS, LS사우타(LS Sauter) 등 주요 현지 기업과의 전략적 파트너십을 통해 성장세를 강화하고 있다. 버카다 소개 |
More news about: Verkada
Oct 12, 2025, 18:27 ET Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
decrease in CNS lesions was observed. These preliminary results suggest the potential for zipalertinib to treat these patients, warranting future investigation." Authors will report results from the REZILIENT2 study of zipalertinib against active CNS metastases
More news about: Taiho Oncology
Oct 10, 2025, 15:31 ET Alamar Biosciences Luncurkan NULISAqpcr™ BD-pTau217 Assay: Terobosan Deteksi Biomarker Non Invasif Khusus Otak Untuk Penelitian Penyakit Alzheimer
menjadi kandidat uji klinis terapi modifikasi penyakit." Tersedia sebagai NULISAqpcr assay single-plex atau dalam NULISAseq™ CNS Disease Panel 120 multipleks, BD-pTau217 assay akan mendukung penelitian penemuan maupun penelitian translasi. Alur kerja otomatis pada uji ini memungkinkan
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:33 ET Alamar Biosciences запускает анализ NULISAqpcr™ BD-pTau217 -- Прорывное достижение в неинвазивных методах обнаружения специфических биомаркеров мозга для исследований болезни Альцгеймера
лечения, модифицирующих заболевание». Доступный в виде однокомпонентного анализа NULISAqpcr или в мультиплексной панели NULISAseq™ CNS Disease Panel 120, анализ BD-pTau217 будет поддерживать как открытия, так и трансляционные исследования. Автоматизированная рабочая процедура анализа
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:11 ET Společnost Alamar Biosciences uvádí na trh test NULISAqpcr™ BD-pTau217: průlom v neinvazivní detekci biomarkerů specifických pro mozek v rámci výzkumu Alzheimerovy choroby
tauopatií. Tento první test svého druhu je jediným dostupným singleplexovým řešením odvozeným z mozku a stanovuje nový standard pro přesnost a specifičnost CNS (centrálního nervového systému) ve výzkumu neurodegenerativních onemocnění.
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:06 ET Alamar Biosciences uvádza na trh test NULISAqpcr™ BD-pTau217: Prevratnú novinku v neinvazívnej detekcii biomarkerov špecifických pre mozog na výskum Alzheimerovej choroby
prvý test svojho druhu je jediným dostupným jednoplexným riešením odvodeným od mozgu, ktorý stanovuje nové kritérium pre presnosť a špecificitu pre CNS vo výskume neurodegeneratívnych ochorení.
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:03 ET Alamar Biosciences wprowadza test NULISAqpcr™ BD-pTau217: Przełom w dziedzinie nieinwazyjnego wykrywania swoistych dla mózgu biomarkerów stosowanych w badaniach choroby Alzheimera
choroby". Dostępne w formie jednoparametrowego testu NULISAqpcr lub w ramach panelu chorób ośrodkowego układu nerwowego NULISAseq™ CNS Disease Panel 120, rozwiązanie BD-pTau217 sprawdzi się zarówno w badaniach ukierunkowanych na nowe odkrycia jak i w badaniach translacyjnych. Zautomatyzowany
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 13:46 ET Alamar Biosciences bringt NULISAqpcr™ BD-pTau217 Assay auf den Markt: Durchbruch beim nicht-invasiven, hirnspezifischen Biomarker-Nachweis für die Alzheimer-Forschung
Therapien in Frage kommen." Der BD-pTau217-Assay ist als Single-Plex-NULISAqpcr-Assay oder im Rahmen des Multiplex-NULISAseq™ CNS Disease Panel 120 erhältlich und unterstützt sowohl die Forschung als auch die translationale Forschung. Der automatisierte Arbeitsablauf des Assays
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 12:35 ET Alamar Biosciences lance le test NULISAqpcr™ BD-pTau217 : une avancée dans la détection non invasive de biomarqueurs spécifiques au cerveau pour la recherche sur la maladie d'Alzheimer
de modification de la maladie. » Disponible en tant que test NULISAqpcr simple-plex ou au sein du panel multiplex NULISAseq™ CNS Disease Panel 120, le test BD-pTau217 soutiendra à la fois la recherche de découverte et la recherche translationnelle. Le flux de travail automatisé
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 10:32 ET Alamar Biosciences 推出 NULISAqpcr™ BD-pTau217 檢測：阿茲海默症研究的非侵入性兼腦部特定生物標記檢測的突破
的專利 NULISA™ 平台，為非侵入性樣本類型（例如：血漿、血清和乾血斑）提供前所未有的靈敏度和特異度。本研究檢測直接測量 CNS 衍生的 pTau217，毋須腦脊液 (CSF) 收集或正子斷層造影 (PET)，這免除現時於人口為本研究或縱向臨床試驗中廣泛採用的障礙。 Alamar Biosciences 創辦人、董事長兼行政總裁 Yuling Luo 博士表示：「NULISAqpcr BD-pTau217 檢測，重新定義 CNS 生物標記定量的可能。現在研究人員可透過從 Tau 週邊來源去除雜訊，而更早兼更準確地檢測有意義的大腦變化。」
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 09:00 ET Next-Generation AI-Driven SyncAR® Spine Receives FDA Clearance for Spine Surgery
surgery. Surgical Theater will premiere this updated platform at two major upcoming events: the Congress of Neurological Surgeons (CNS) Annual Meeting and the North American Spine Society (NASS) Annual Meeting, where global spine leaders will have the opportunity to experience its newest
More news about: Surgical Theater
Oct 10, 2025, 07:48 ET Alamar Biosciences lanza el ensayo NULISAqpcr™ BD-pTau217 para la investigación de la enfermedad de Alzheimer
terapias modificadoras de la enfermedad". Disponible como ensayo NULISAqpcr de plexo simple o dentro del panel multiplex NULISAseq™ CNS Disease Panel 120, el ensayo BD-pTau217 facilitará tanto la investigación de descubrimiento como la traslacional. Su flujo de trabajo automatizado permite
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 07:45 ET Alamar Biosciences、非侵襲的かつ脳特異的なアルツハイマー病研究用バイオマーカー検出における革新技術「NULISAqpcr™ BD-pTau217アッセイ」を発表
を検出するうえで大きな可能性を示しており、疾患修飾療法の臨床試験候補者を特定する手がかりとなる可能性があります。」 BD-pTau217アッセイは、シングルプレックスのNULISAqpcrアッセイとして、またはマルチプレックスのNULISAseq™ CNS Disease Panel 120内の一部として提供され、創薬研究およびトランスレーショナルリサーチの双方を支援します。このアッセイの自動化ワークフローは、ARGO™ HT Systemを用いて1日に220検体以上を処理できるため、疾患コホートや集団ベース研究におけるハイスループット解析に最適です。
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 07:39 ET 알라마 바이오사이언스, NULISAqpcr™ BD-pTau217 분석법 출시: 알츠하이머병 치료를 목적으로 한 비침습적 뇌 내 바이오마커 검출 방식의 획기적인 진전
머지않아 연구 환경에서 다중 분석법으로 측정한 뇌 내 pTaus로 이런 환자의 병증을 검출할 수 있을 것으로 기대된다"라고 평했다. BD-pTau217 분석법은 신약 개발 혹은 중개 연구에 단일 검사 방식의 NULISAqpcr 분석법으로 사용하거나 다중 검사 방식의 NULISAseq™ CNS Disease Panel 120과 함께 사용할 수 있다. 이 분석법은 워크플로가 자동화되어 있어 ARGO™ HT 시스템으로 하루에 220개 이상의 검체를 처리할 수 있다. 따라서 코호트 연구나 다수를 대상으로 한 연구 목적으로 다량의 검체를 분석하는 데 이상적이다.
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 07:30 ET Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
may cause side effects. Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist
More news about: Johnson & Johnson